EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Avelumab first‐line maintenance in advanced urothelial carcinoma: Complete screening for prognostic and predictive factors using machine learning in the JAVELIN Bladder 100 phase 3 trial

Juliane Manitz, Aslihan Gerhold-Ay, Pascal Kieslich iD, Parantu Shah, Thomas Mrowiec, Karin Tyroller

Cancer Medicine · 2024

DOI: 10.1002/cam4.7411 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Cancer Medicine, 2024. Verfasst von Juliane Manitz und 5 weiteren Autor:innen. Beteiligte Einrichtung: EMD Serono, Billerica, Massachusetts, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Machine Learning, Urinary Bladder Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer, the healthcare business of Merck KGaA, Darmstadt, Germany (CrossRef Funder ID: 10.13039/100009945).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Avelumab first‐line (1 L) maintenance is a standard of care for advanced urothelial carcinoma (aUC) based on the JAVELIN Bladder 100 phase 3 trial, which showed that avelumab 1 L maintenance + best supportive care (BSC) significantly prolonged overall survival (OS) and progression‐free survival (PFS) vs BSC alone in patients who were progression free after receiving 1 L platinum‐containing chemotherapy. Here, we comprehensively screened JAVELIN Bladder 100 trial datasets to identify prognostic factors that define subpopulations of patients with longer or shorter OS irrespective of treatment, and predictive factors that select patients who could obtain a greater OS benefit from avelumab 1 L maintenance treatment.

Methods

We performed machine learning analyses to screen a large set of baseline covariates, including patient demographics, disease characteristics, laboratory values, molecular biomarkers, and patient‐reported outcomes. Covariates were identified from previously reported analyses and established prognostic and predictive markers. Variables selected from random survival forest models were processed further in univariate Cox models with treatment interaction and visually inspected using correlation analysis and Kaplan–Meier curves. Results were summarized in a multivariable Cox model.

Results

Prognostic baseline covariates associated with OS included in the final model were assignment to avelumab 1 L maintenance treatment, Eastern Cooperative Oncology Group performance status, site of metastasis, sum of longest target lesion diameters, levels of C‐reactive protein and alkaline phosphatase in blood, lymphocyte proportion in intratumoral stroma, tumor mutational burden, and tumor CD8+ T‐cell infiltration. Potential predictive factors included site of metastasis, tumor mutation burden, and tumor CD8+ T‐cell infiltration. An analysis in patients with PD‐L1+ tumors had similar findings to those in the overall population.

Conclusions

Machine learning analyses of data from the JAVELIN Bladder 100 trial identified potential prognostic and predictive factors for avelumab 1 L maintenance treatment in patients with aUC, which warrant further evaluation in other clinical datasets.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedMachine LearningUrinary Bladder NeoplasmsHumansMaleFemalePrognosisAgedMiddle AgedCarcinoma, Transitional CellMaintenance ChemotherapyAntineoplastic Agents, ImmunologicalProgression-Free SurvivalBiomarkers, Tumor

Stichwörter der Autor:innen

biomarkersclinical cancer researchclinical trialsprognostic factorurothelial

Substanzen

avelumabAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalBiomarkers, Tumor

Autor:innen und Institutionen

  • EMD Serono, Billerica, Massachusetts, USA.
  • The healthcare business of Merck KGaA, Darmstadt, Germany.

ORCID-Profile: Pascal Kieslich

Förderung

  • Pfizer
  • the healthcare business of Merck KGaA, Darmstadt, Germany (CrossRef Funder ID: 10.13039/100009945)

Zitieren

APA

Manitz, J., Gerhold-Ay, A., Kieslich, P., Shah, P., Mrowiec, T., & Tyroller, K. (2024). Avelumab first‐line maintenance in advanced urothelial carcinoma: Complete screening for prognostic and predictive factors using machine learning in the JAVELIN Bladder 100 phase 3 trial. Cancer Medicine. https://doi.org/10.1002/cam4.7411

Vancouver

Manitz J, Gerhold-Ay A, Kieslich P, Shah P, Mrowiec T, Tyroller K. Avelumab first‐line maintenance in advanced urothelial carcinoma: Complete screening for prognostic and predictive factors using machine learning in the JAVELIN Bladder 100 phase 3 trial. Cancer Medicine. 2024. doi:10.1002/cam4.7411

BibTeX
@article{Manitz2024,
  author = {Manitz, Juliane and Gerhold-Ay, Aslihan and Kieslich, Pascal and Shah, Parantu and Mrowiec, Thomas and Tyroller, Karin},
  title = {Avelumab first‐line maintenance in advanced urothelial carcinoma: Complete screening for prognostic and predictive factors using machine learning in the JAVELIN Bladder 100 phase 3 trial},
  journal = {Cancer Medicine},
  year = {2024},
  doi = {10.1002/cam4.7411}
}
Kostenlos starten →